الفهرس 
Pathophysiology of Parkinson’s diseaseOnly 14 pages are availabe for public view
 |  | from | 185 |  |  |
| | | from | 185 | | |
Abstract
Parkinson's disease (PD) represents the second most common
degenerative disease of the central nervous system (CNS). Due to
the high level of misdiagnosis, there is strong need for a diagnostic
biomarker for PD. Alpha-synuclein plays a critical role in the
pathogenesis of PD. The close relation between the salivary glands
and the CNS could render their secretions as a useful pool of
biomarkers. Aim of the work: To investigate salivary total and
oligomeric Alpha-synuclein proteins as potential biomarkers in PD
patients and to correlate them with PD severity and cognitive
functions. Patients: Twenty five patients with PD and fifteen age
and sex matched healthy subjects, as a control group, were
enrolled. Methods: A complete clinical examination and
evaluation was performed using Unified Parkinson's Disease
Rating Scale (UPDRS), Modified Hoehn and Yahr staging scale
(MH&S) Beck Depression Inventory (BDI), Montreal Cognitive
Assessment (MoCA) and Frontal Assessment Battery (FAB),
Parkinson’s Disease-Cognitive Rating Scale (PD-CRS). Samples of
saliva were analyzed by specific antiasyn and antioligomeric asyn
ELISA kits. Results: There was a statistically significant
difference in oligomer, total, and oligomer /total ratio of alpha
synuclein level. There was a statistically significance difference in
MOCA, FAB and PDCRS. There was a statistically significant
positive correlation between oligomer-alpha synuclein level and
disease duration and between years of education and PDCRS.
Conclusions: Salivary alpha synuclein total and oligomer can be
used as potential biomarkers for diagnosis of PD but have no role
as biomarkers for disease severity or cognitive dysfunction in PD
patients.
Keywords: Parkinson's disease, biomarkers, salivary alpha
synuclein, PD severity, cognitive dysfunction.